Priscilla K. Brastianos
YOU?
Author Swipe
View article: RADT-42. NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
RADT-42. NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY Open
Tumor-infiltrating lymphocyte (TIL) therapy is an emerging treatment option for treatment-refractory melanoma. TIL therapy involves tumor harvest, isolation and ex vivo expansion of TILs, followed by lymphodepletion prior to infusion. TIL …
View article: EXTH-33. The oncolytic adenovirus RGDOX sensitizes the anti-tumor efficacy of immune checkpoint blockades in murine melanoma brain metastases models
EXTH-33. The oncolytic adenovirus RGDOX sensitizes the anti-tumor efficacy of immune checkpoint blockades in murine melanoma brain metastases models Open
Amongst solid cancers, melanoma brain metastases (MBM) have the highest likelihood of metastasizing to the brain. The use of immune checkpoint inhibitors (ICI) for metastatic melanoma has emerged as first line therapy; however, intracrania…
View article: INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab
INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab Open
PURPOSE Patients with melanoma brain metastases (MBM) have a poor prognosis despite improvements in treatments. The combination of ipilimumab and nivolumab remains the standard of care for this patient population and there is limited data …
View article: P11.18.A ROLE OF RADIOTHERAPY IN RESECTED NON-SMALL CELL LUNG CANCER BRAIN METASTASES TREATED WITH CNS-ACTIVE TYROSINE KINASE INHIBITORS
P11.18.A ROLE OF RADIOTHERAPY IN RESECTED NON-SMALL CELL LUNG CANCER BRAIN METASTASES TREATED WITH CNS-ACTIVE TYROSINE KINASE INHIBITORS Open
BACKGROUND For patients (pts) with non-small cell lung cancer (NSCLC) with targetable genomic alterations (TGAs), the increased CNS activity of 2nd/3rd-gen tyrosine kinase inhibitors (CNS-TKIs) has transformed the treatment of intact brain…
View article: P11.19.B NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
P11.19.B NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY Open
BACKGROUND Tumor-infiltrating lymphocyte (TIL) therapy is an emerging treatment option for treatment-refractory melanoma, FDA-approved in 2024. TIL therapy involves tumor harvest, isolation and ex vivo expansion of TIL, followed by lymphod…
View article: Nascent Clinical Experience with Radiotherapeutic Management of Melanoma Brain Metastases in Patients Treated with Tumor-Infiltrating Lymphocyte (TIL) Therapy
Nascent Clinical Experience with Radiotherapeutic Management of Melanoma Brain Metastases in Patients Treated with Tumor-Infiltrating Lymphocyte (TIL) Therapy Open
View article: RDTA-20 BRAIN-DIRECTED RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH MELANOMA BRAIN METASTASES TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
RDTA-20 BRAIN-DIRECTED RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH MELANOMA BRAIN METASTASES TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY Open
PURPOSE Tumor-infiltrating lymphocyte (TIL) therapy is an emerging option for treatment-refractory melanoma. Studies for TIL therapy approval excluded patients with uncontrolled melanoma brain metastases (MBMs). Given the timeline from TIL…
View article: Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging Open
View article: Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A
Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A Open
KRAS mutations are prevalent in brain metastases (BM) from non-small cell lung cancer (NSCLC). The activity of KRAS-G12C selective, brain-penetrant small molecule inhibitor adagrasib was recently demonstrated in preclinical models of BM an…
View article: RANO criteria for response assessment of brain metastases based on amino acid PET imaging
RANO criteria for response assessment of brain metastases based on amino acid PET imaging Open
View article: Collision tumor, a metastatic melanoma within a meningioma: a case report
Collision tumor, a metastatic melanoma within a meningioma: a case report Open
View article: Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review
Screening for brain metastases in patients with advanced non-small cell lung cancer and an actionable genomic alteration: A structured literature review Open
Background Brain metastases (BM) frequently occur in patients with non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGA). Targeted therapies (TTs) improve outcomes, but differences in BM screening and eligibility cri…
View article: Real-world outcomes in patients with brain metastases secondary to HR+/HER2− MBC treated with abemaciclib and local intracranial therapy
Real-world outcomes in patients with brain metastases secondary to HR+/HER2− MBC treated with abemaciclib and local intracranial therapy Open
Background Real-world data are limited for patients with brain metastases secondary to metastatic breast cancer (MBC) and treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This study describes real-world outcomes in patients w…
View article: Supplementary Material and Methods from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Supplementary Material and Methods from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Supplementary Material and Methods
View article: Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Supplementary Table 1
View article: Supplementary Material and Methods from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Supplementary Material and Methods from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Supplementary Material and Methods
View article: Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Supplementary Figures S1-S10
View article: Data from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Data from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Advances in drug treatments for brain metastases of breast cancer have improved progression free survival but new, more efficacious strategies are needed. Most chemotherapeutic drugs infiltrate brain metastases by moving between brain capi…
View article: Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Supplementary Table 1 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Supplementary Table 1
View article: Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Supplementary Figure S1-S10 from Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer Open
Supplementary Figures S1-S10
View article: cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas Open
Meningiomas are the most frequent primary intracranial tumors. Hence, they constitute a major share of diagnostic specimens in neuropathology practice. The 2021 WHO Classification of Central Nervous System Tumors (“CNS5”) has introduced th…
View article: Thrombosis, brain metastasis formation, and the perivascular metastatic niche—Novel insights from the tumor microvascular circulation
Thrombosis, brain metastasis formation, and the perivascular metastatic niche—Novel insights from the tumor microvascular circulation Open
View article: Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma
Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma Open
View article: Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape Open
Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases. Current treatments for this subgroup of patients with advanced NSCLC include local therapies (surgery, stereotactic radiosurgery…
View article: Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions Open
Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specif…
View article: Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma
Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma Open
Delays and risks associated with neurosurgical biopsies preclude timely diagnosis and treatment of central nervous system (CNS) lymphoma and other CNS neoplasms. We prospectively integrated targeted rapid genotyping of cerebrospinal fluid …
View article: Evolving concepts in meningioma management in the era of genomics
Evolving concepts in meningioma management in the era of genomics Open
Meningioma is the most common type of primary brain tumor. Surgical resection followed by surveillance is the first‐line treatment for the majority of symptomatic meningiomas; however, recent advances in molecular sequencing, DNA methylati…
View article: Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients Open
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are b…
View article: <i>NAB2::STAT6</i> fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors
<i>NAB2::STAT6</i> fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors Open
Meningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal…
View article: Introduction: Contemporary management of low-grade gliomas: from tumor biology to the patient’s quality of life
Introduction: Contemporary management of low-grade gliomas: from tumor biology to the patient’s quality of life Open
Editorial